{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:41:33Z","timestamp":1761489693750},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,6,17]],"date-time":"2015-06-17T00:00:00Z","timestamp":1434499200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s13063-015-0799-6","type":"journal-article","created":{"date-parts":[[2015,6,16]],"date-time":"2015-06-16T21:31:20Z","timestamp":1434490280000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["AMBITION-cm: intermittent high dose AmBisome on a high dose fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: study protocol for a randomized controlled trial"],"prefix":"10.1186","volume":"16","author":[{"given":"Mooketsi","family":"Molefi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awilly A.","family":"Chofle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00edle F.","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Kalluvya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John M.","family":"Changalucha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Cainelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tshepo","family":"Leeme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nametso","family":"Lekwape","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drew W.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Haverkamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory P.","family":"Bisson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emili","family":"Letang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme","family":"Meintjes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosie","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tariro","family":"Makadzange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiratidzo E.","family":"Ndhlovu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph N.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,17]]},"reference":[{"issue":"4","key":"799_CR1","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","volume":"23","author":"BJ Park","year":"2009","unstructured":"Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS. AIDS (London, England). 2009;23(4):525\u201330.","journal-title":"AIDS (London, England)"},{"issue":"5","key":"799_CR2","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/cid\/cit794","volume":"58","author":"JN Jarvis","year":"2014","unstructured":"Jarvis JN, Bicanic T, Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated Cryptococcal meningitis: implications for improving outcomes. Clin Infect Dis. 2014;58(5):736\u201345.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"799_CR3","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cid\/cit019","volume":"56","author":"GP Bisson","year":"2013","unstructured":"Bisson GP, Molefi M, Bellamy S, et al. Early versus delayed antiretroviral therapy and cerebrospinal fluid fungal clearance in adults with HIV and cryptococcal meningitis. Clin Infect Dis. 2013;56(8):1165\u201373.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"799_CR4","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.3109\/13693781003774689","volume":"48","author":"KT Steele","year":"2010","unstructured":"Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP. In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med Mycol. 2010;48(8):1112\u20135.","journal-title":"Med Mycol"},{"issue":"6","key":"799_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0067311","volume":"8","author":"C Rothe","year":"2013","unstructured":"Rothe C, Sloan DJ, Goodson P, et al. A prospective longitudinal study of the clinical outcomes from cryptococcal meningitis following treatment induction with 800 mg oral fluconazole in Blantyre, Malawi. PLoS One. 2013;8(6), e67311.","journal-title":"PLoS One"},{"key":"799_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1758-2652-14-48","volume":"14","author":"BM Wajanga","year":"2011","unstructured":"Wajanga BM, Kalluvya S, Downs JA, Johnson WD, Fitzgerald DW, Peck RN. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study. J Int AIDS Soc. 2011;14:48.","journal-title":"J Int AIDS Soc"},{"issue":"9423","key":"799_CR7","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/S0140-6736(04)16301-0","volume":"363","author":"AE Brouwer","year":"2004","unstructured":"Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet. 2004;363(9423):1764\u20137.","journal-title":"Lancet"},{"issue":"14","key":"799_CR8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1056\/NEJMoa1110404","volume":"368","author":"JN Day","year":"2013","unstructured":"Day JN, Chau TT, Wolbers M, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;368(14):1291\u2013302.","journal-title":"N Engl J Med"},{"issue":"3","key":"799_CR9","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291\u2013322.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"799_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.7196\/sajhivmed.899","volume":"14","author":"NP Govender","year":"2013","unstructured":"Govender NP, Meintjes G, Bicanic T, et al. Guideline for the prevention, diagnosis and management of cryptococcal meningitis among HIV-infected persons: 2013 update. Southern African J HIV Med. 2013;14(2):76\u201386.","journal-title":"Southern African J HIV Med"},{"issue":"4","key":"799_CR11","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3201\/eid2004.131277","volume":"20","author":"R Rajasingham","year":"2014","unstructured":"Rajasingham R, Williams D, Meya DB, Meintjes G, Boulware DR, Scriven J. Nosocomial drug-resistant bacteremia in 2 cohorts with cryptococcal meningitis, Africa. Emerg Infect Dis. 2014;20(4):722\u20134.","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"799_CR12","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1093\/jac\/dkt221","volume":"68","author":"A Loyse","year":"2013","unstructured":"Loyse A, Dromer F, Day J, Lortholary O, Harrison TS. Flucytosine and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J Antimicrobial Chemotherapy. 2013;68(11):2435\u201344.","journal-title":"J Antimicrobial Chemotherapy"},{"issue":"7","key":"799_CR13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S1473-3099(13)70078-1","volume":"13","author":"A Loyse","year":"2013","unstructured":"Loyse A, Thangaraj H, Easterbrook P, et al. Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countries. Lancet Infect Dis. 2013;13(7):629\u201337.","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"799_CR14","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1086\/593194","volume":"47","author":"N Longley","year":"2008","unstructured":"Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis. 2008;47(12):1556\u201361.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"799_CR15","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/QAI.0000000000000147","volume":"66","author":"J Meda","year":"2014","unstructured":"Meda J, Kalluvya S, Downs JA, et al. Cryptococcal meningitis management in Tanzania with strict schedule of serial lumber punctures using intravenous tubing sets: an operational research study. J Acquired Immune Deficiency Syndromes (1999). 2014;66(2):e31\u20136.","journal-title":"J Acquired Immune Deficiency Syndromes (1999)"},{"issue":"1","key":"799_CR16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jinf.2011.10.014","volume":"64","author":"CK Muzoora","year":"2011","unstructured":"Muzoora CK, Kabanda T, Ortu G, et al. Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. J Infection. 2011;64(1):76\u201381.","journal-title":"J Infection"},{"issue":"11","key":"799_CR17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1097\/QAD.0b013e328354b419","volume":"26","author":"A Jackson","year":"2012","unstructured":"Jackson A, Nussbaum J, Phulusa J, et al. A phase II randomised controlled trial adding oral flucytosine to high dose fluconazole, with short-course amphotericin B, for cryptococcal meningitis in Malawi. AIDS (London, England). 2012;26(11):1363\u201370.","journal-title":"AIDS (London, England)"},{"issue":"1","key":"799_CR18","first-page":"e00725","volume":"5","author":"J Livermore","year":"2013","unstructured":"Livermore J, Howard SJ, Sharp AD, et al. Efficacy of an abbreviated induction regimen of amphotericin B deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy is equivalent to 14 days. MBio. 2013;5(1):e00725\u201313.","journal-title":"MBio"},{"issue":"6","key":"799_CR19","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1093\/jac\/dkl141","volume":"57","author":"H Vogelsinger","year":"2006","unstructured":"Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrobial Chemotherapy. 2006;57(6):1153\u201360.","journal-title":"J Antimicrobial Chemotherapy"},{"issue":"10","key":"799_CR20","doi-asserted-by":"publisher","first-page":"5303","DOI":"10.1128\/AAC.00933-12","volume":"56","author":"WW Hope","year":"2012","unstructured":"Hope WW, Goodwin J, Felton TW, Ellis M, Stevens DA. Population pharmacokinetics of conventional and intermittent dosing of liposomal amphotericin B in adults: a first critical step for rational design of innovative regimens. Antimicrob Agents Chemother. 2012;56(10):5303\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"799_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/infdis\/jit164","volume":"208","author":"L O'Connor","year":"2013","unstructured":"O'Connor L, Livermore J, Sharp AD, et al. Pharmacodynamics of liposomal amphotericin B and flucytosine for cryptococcal meningoencephalitis: safe and effective regimens for immunocompromised patients. J Infectious Diseases. 2013;208(2):351\u201361.","journal-title":"J Infectious Diseases"},{"issue":"9","key":"799_CR22","doi-asserted-by":"publisher","first-page":"3664","DOI":"10.1128\/AAC.01448-08","volume":"53","author":"PO Gubbins","year":"2009","unstructured":"Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. Pharmacokinetics and buccal mucosal concentrations of a 15 milligram per kilogram of body weight total dose of liposomal amphotericin B administered as a single dose (15 mg\/kg), weekly dose (7.5 mg\/kg), or daily dose (1 mg\/kg) in peripheral stem cell transplant patients. Antimicrob Agents Chemother. 2009;53(9):3664\u201374.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"799_CR23","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","volume":"12","author":"P Mehta","year":"2006","unstructured":"Mehta P, Vinks A, Filipovich A, et al. High-dose weekly Ambisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant. 2006;12(2):235\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"799_CR24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1056\/NEJMoa0903627","volume":"362","author":"S Sundar","year":"2010","unstructured":"Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(6):504\u201312.","journal-title":"N Engl J Med"},{"issue":"10","key":"799_CR25","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/514341","volume":"44","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289\u201397.","journal-title":"Clin Infect Dis"},{"issue":"Suppl 2","key":"799_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1468-1293.2011.00944_1.x","volume":"12","author":"M Nelson","year":"2011","unstructured":"Nelson M, Dockrell D, Edwards S, et al. British HIV Association and British Infection Association guidelines for the treatment of opportunistic infection in HIV-seropositive individuals 2011. HIV Medicine. 2011;12 Suppl 2:1\u2013140.","journal-title":"HIV Medicine"},{"issue":"2","key":"799_CR27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1086\/653606","volume":"51","author":"RJ Hamill","year":"2010","unstructured":"Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety. Clin Infect Dis. 2010;51(2):225\u201332.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"799_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/cid\/cir745","volume":"54","author":"A Loyse","year":"2011","unstructured":"Loyse A, Wilson D, Meintjes G, et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;54(1):121\u20138.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"799_CR29","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1086\/599112","volume":"48","author":"PG Pappas","year":"2009","unstructured":"Pappas PG, Chetchotisakd P, Larsen RA, et al. A phase II randomized trial of amphotericin B alone or combined with fluconazole in the treatment of HIV-associated cryptococcal meningitis. Clin Infect Dis. 2009;48(12):1775\u201383.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"799_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/518607","volume":"45","author":"T Bicanic","year":"2007","unstructured":"Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45(1):76\u201380.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"799_CR31","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1086\/588792","volume":"47","author":"T Bicanic","year":"2008","unstructured":"Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis. 2008;47(1):123\u201330.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"799_CR32","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/649861","volume":"50","author":"JC Nussbaum","year":"2009","unstructured":"Nussbaum JC, Jackson A, Namarika D, et al. Combination flucytosine and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin Infect Dis. 2009;50(3):338\u201344.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"799_CR33","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1097\/QAD.0b013e3283536a93","volume":"26","author":"JN Jarvis","year":"2012","unstructured":"Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-gamma immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS (London, England). 2012;26(9):1105\u201313.","journal-title":"AIDS (London, England)"},{"issue":"5","key":"799_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1086\/604716","volume":"49","author":"T Bicanic","year":"2009","unstructured":"Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin Infect Dis. 2009;49(5):702\u20139.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"799_CR35","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1097\/QAI.0b013e318183181e","volume":"49","author":"GP Bisson","year":"2008","unstructured":"Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquired Immune Deficiency Syndromes (1999). 2008;49(2):227\u20139.","journal-title":"J Acquired Immune Deficiency Syndromes (1999)"},{"issue":"11","key":"799_CR36","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1086\/587667","volume":"46","author":"A Kambugu","year":"2008","unstructured":"Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis. 2008;46(11):1694\u2013701.","journal-title":"Clin Infect Dis"},{"issue":"9306","key":"799_CR37","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S0140-6736(02)07750-4","volume":"359","author":"KF Schulz","year":"2002","unstructured":"Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against deciphering. Lancet. 2002;359(9306):614\u20138.","journal-title":"Lancet"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0799-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-015-0799-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0799-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-015-0799-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T16:06:24Z","timestamp":1599149184000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-015-0799-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,17]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["799"],"URL":"https:\/\/doi.org\/10.1186\/s13063-015-0799-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,17]]},"assertion":[{"value":"12 December 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"276"}}